AEZS.TO

Aeterna Zentaris Inc. [AEZS.TO] Stock Forecast

Q: What is Aeterna Zentaris Inc. stock symbol ?

Aeterna Zentaris Inc. is a US stock, located in Summerville of Sc and trading under the symbol AEZS.TO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AEZS.TO Stock Summary

AEZS.TO has more than 2 years of cash runway (25 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Does not have any significance market cap ($13.55M)

Profit margins (-4.65%) are lower than the previous year (-3.68%)

Top 10 Correlated Stocks

AEZS.TO

In the News

AEZS.TO Financial details

Company Rating

Sell

Market Cap

13.55M

Income

-16.66M

Revenue

4.5M

Book val./share

3.75

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 May 2024

P/E

-0.33

Forward P/E

PEG

0.07

P/S

1.53

P/B

0.4

P/C

0.38

P/FCF

-0.69

Quick Ratio

9.32

Current Ratio

9.91

Debt / Equity

0.02

LT Debt / Equity

0.01

EPS (TTM)

-3.43

EPS next Y

EPS next Q

EPS this Y

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

53.26%

Revenue Q/Q

3933.33%

EPS Q/Q

36.47%

SMA20

SMA50

50%

SMA100

50%

Inst Own

Inst Trans

ROA

-75%

ROE

-104%

ROC

-0.41%

Gross Margin

97%

Oper. Margin

-228%

Profit Margin

-465%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.91-4.48

52W High

-33.25%

52W Low

+167%

RSI

Rel Volume

0.1

Avg Volume

1.86K

Volume

179

Perf Week

-5.32%

Perf Month

3.49%

Perf Quarter

27.14%

Perf Half Y

8.98%

Beta

2.07

Volatility

0.04%, 0.1%

Prev Close

Price

2.67

Change

AEZS.TO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.77	2.22	1.14	1.16	0
Net income per share	-8.75	-3.11	-1.82	-6.22	0
Operating cash flow per share	-15.53	-2.51	-1.87	-2.82	0
Free cash flow per share	-15.53	-2.51	-2.01	-2.82	0
Cash per share	11.35	14.77	14.2	10.42	0
Book value per share	-3.57	8.04	11.53	7.37	0
Tangible book value per share	-15.28	2.64	9.62	7.37	0
Share holders equity per share	-3.57	8.04	11.53	7.37	0
Interest debt per share	2.17	0.56	0.04	0.04	0
Market cap	15.81M	17.42M	41.48M	15.41M	0
Enterprise value	8.87M	-6.67M	-23.66M	-35.02M	-33.74M
P/E ratio	-2.62	-3.4	-4.96	-0.51	0
Price to sales ratio	29.71	4.77	7.89	2.73	0
POCF ratio	-1.47	-4.22	-4.83	-1.13	0
PFCF ratio	-1.47	-4.22	-4.5	-1.13	0
P/B Ratio	-6.42	1.32	0.78	0.43	0
PTB ratio	-6.42	1.32	0.78	0.43	0
EV to sales	16.68	-1.83	-4.5	-6.21	-7.5
Enterprise value over EBITDA	-0.96	0.84	2.77	4.58	1.86
EV to operating cash flow	-0.83	1.61	2.76	2.56	1.97
EV to free cash flow	-0.83	1.61	2.57	2.56	1.97
Earnings yield	-0.38	-0.29	-0.2	-1.96	0
Free cash flow yield	-0.68	-0.24	-0.22	-0.89	0
Debt to equity	-0.37	0.01	0	0.01	0.02
Debt to assets	0.05	0	0	0	0.01
Net debt to EBITDA	0.75	3.05	7.64	6.6	1.86
Current ratio	1.93	5.56	9.12	7.88	8.01
Interest coverage	-16.09	-8.24	-412.9	-5.08K	0
Income quality	1.78	0.81	1.03	0.6	1.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	12.43	1.3	1.12	1.46	1.94
Research and developement to revenue	3.45	0.41	1.25	2.22	3.01
Intangibles to total assets	0.4	0.24	0.11	0	0
Capex to operating cash flow	0	0	0.07	0	0
Capex to revenue	0	0	-0.12	0	0
Capex to depreciation	0	0	-4.41	-0.08	-0.11
Stock based compensation to revenue	1.49	0.02	0.06	0.1	0.08
Graham number	26.5	23.73	21.73	32.11	0
ROIC	14.09	-0.48	-0.16	-0.56	-0.88
Return on tangible assets	-0.51	-0.18	-0.12	-0.54	-0.45
Graham Net	-19.57	0.9	8.91	6.61	0
Working capital	5.25M	22.87M	63.05M	48.44M	31.83M
Tangible asset value	-10.55M	4.34M	44.23M	35.78M	18.2M
Net current asset value	-11.53M	3.82M	43.7M	35.24M	17.55M
Invested capital	-0.37	0.01	0	0.01	0.02
Average receivables	476K	1.17M	2.68M	2.92M	1.25M
Average payables	1.18M	1.14M	1.06M	1.49M	1.95M
Average inventory	721.5K	612K	47K	151K	147.5K
Days sales outstanding	451.45	168.01	255.01	139.79	27.83
Days payables outstanding	967.7	186.99	3.79K	4.74K	3.07K
Days of inventory on hand	1.07K	3.31	296.06	532.39	108.51
Receivables turnover	0.81	2.17	1.43	2.61	13.11
Payables turnover	0.38	1.95	0.1	0.08	0.12
Inventory turnover	0.34	110.33	1.23	0.69	3.36
ROE	2.45	-0.39	-0.16	-0.84	-0.91
Capex per share	0	0	-0.14	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.51	0.44	0.46	0	0.02
Net income per share	-4.3	-0.9	-0.52	-0.85	-1.16
Operating cash flow per share	-0.71	-0.84	-0.88	-0.7	-1.11
Free cash flow per share	-0.7	-0.84	-0.88	-0.7	-1.11
Cash per share	10.42	9.59	8.69	7.98	7
Book value per share	7.37	6.43	5.99	5.41	3.75
Tangible book value per share	7.37	6.43	5.99	5.41	3.75
Share holders equity per share	7.37	6.43	5.99	5.41	3.75
Interest debt per share	1.78	0.05	0.05	0.04	0.06
Market cap	15.41M	12.07M	12.24M	11.93M	9.41M
Enterprise value	-35.02M	-34.28M	-29.72M	-26.61M	-24.32M
P/E ratio	-0.18	-0.69	-1.22	-0.72	-0.42
Price to sales ratio	6.2	5.67	5.45	3.98K	77.79
POCF ratio	-4.5	-2.97	-2.85	-3.53	-1.75
PFCF ratio	-4.56	-2.97	-2.85	-3.52	-1.75
P/B Ratio	0.43	0.39	0.42	0.45	0.52
PTB ratio	0.43	0.39	0.42	0.45	0.52
EV to sales	-14.09	-16.11	-13.23	-8.87K	-201.03
Enterprise value over EBITDA	8.82	8.35	10.47	5.92	3.61
EV to operating cash flow	10.23	8.44	6.92	7.86	4.52
EV to free cash flow	10.37	8.44	6.92	7.84	4.52
Earnings yield	-1.36	-0.36	-0.21	-0.35	-0.6
Free cash flow yield	-0.22	-0.34	-0.35	-0.28	-0.57
Debt to equity	0.01	0.01	0.01	0.01	0.02
Debt to assets	0	0	0	0.01	0.01
Net debt to EBITDA	12.7	11.28	14.78	8.57	5.01
Current ratio	7.88	7.88	11.26	9.91	8.01
Interest coverage	-0.47	-87.65	0	0	0
Income quality	0.27	0.95	1.7	0.82	0.95
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.17	0	0	597	21.44
Research and developement to revenue	1.78	1.89	1.3	917	31.97
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.01	0	0	0	0
Capex to revenue	0.02	0	0	-3	-0.04
Capex to depreciation	1.48	-0.05	-0.07	-0.21	-0.12
Stock based compensation to revenue	0.02	0.01	0.14	9	0.23
Graham number	26.71	11.4	8.36	10.19	9.89
ROIC	-0.19	-0.14	-0.08	-0.15	-0.29
Return on tangible assets	-0.37	-0.09	-0.05	-0.1	-0.15
Graham Net	6.61	5.79	5.26	4.76	3.19
Working capital	48.44M	44.27M	41.82M	37.68M	31.83M
Tangible asset value	35.78M	31.21M	29.08M	26.28M	18.2M
Net current asset value	35.24M	30.63M	28.49M	25.7M	17.55M
Invested capital	0.01	0.01	0.01	0.01	0.02
Average receivables	2.12M	2.08M	1.49M	819.5K	502.5K
Average payables	1.38M	3.08M	3.85M	3.44M	2.58M
Average inventory	233.5K	228K	160K	92K	78.5K
Days sales outstanding	78.23	84.88	39.15	19.86K	255.12
Days payables outstanding	3.6K	21.86K	2.31K	27K	3.05K
Days of inventory on hand	404.12	1.2K	60.22	744.55	108
Receivables turnover	1.15	1.06	2.3	0	0.35
Payables turnover	0.03	0	0.04	0	0.03
Inventory turnover	0.22	0.07	1.49	0.12	0.83
ROE	-0.58	-0.14	-0.09	-0.16	-0.31
Capex per share	0.01	0	0	0	0

AEZS.TO Frequently Asked Questions

What is Aeterna Zentaris Inc. stock symbol ?

Aeterna Zentaris Inc. is a US stock , located in Summerville of Sc and trading under the symbol AEZS.TO

What is Aeterna Zentaris Inc. stock quote today ?

Aeterna Zentaris Inc. stock price is $2.67 today.

Is Aeterna Zentaris Inc. stock public?

Yes, Aeterna Zentaris Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.86K
Market Capitalization 13.55M
Employee 12
CEO Dr. Klaus Paulini Ph.D.
Headquarters Summerville,SC,US
IPO Date 1996-09-18
Website https://www.zentaris.com

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.